Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF). Because thrombopoietin and erythropoietin signal through JAK2, dose-dependent cytopenias are expected with treatment. In the COMFORT-I (COntrolled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Verstovsek, Srdan, Gotlib, Jason, Gupta, Vikas, Atallah, Ehab, Mascarenhas, John, Quintas-Cardama, Alfonso, Sun, William, Sarlis, Nicholas J, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Mesa, Ruben A
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2013
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869911/
https://ncbi.nlm.nih.gov/pubmed/24368888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S53348
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados